Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

Figures & data

Figure 1. Psoriasis inflammatory cascade. Abbreviations: TNF, tumor necrosis factor; IL, interleukin; Th, T helper; IFN-γ, interferon gamma; γδ T-cells, gamma delta T cells. Elaborated from [14]

Figure 2. QoL improvement at week 12 in FIXTURE, ERASURE, and CLEAR. Data assessed with non-responder imputation

§P < 0.001 for secukinumab vs. placebo and etanercept**P < 0.001 for secukinumab vs. placebo#P < 0.05 for secukinumab vs. ustekinumabUstekinumab dose: 45 mg for patients weighing ≤100 kg at baseline or 90 mg for patient weighing >100 kg. DLQI, Dermatology Life Quality Index; PBO, placebo; QoL, quality of life; SEC, secukinumab; UST, ustekinumab.

Table 1. ERASURE: Results from psoriasis symptoms diary at week 12

	Secukinumab 300 mg (n = 79)	Secukinumab 150 mg (n = 86)	Placebo (n = 84)
Itching Pain Scaling	−5.45 (0.28) ϯ -4.59 (0.32) ϯ -5.49 (0.29) ϯ	−4.86 (0.30) ϯ -3.92 (0.34) ϯ -4.74 (0.31) ϯ	−0.22 (0.26) 0.06 (0.25) -0.11 (0.25)

Ϯ P < 0.001 versus Placebo

Table 2. FIXTURE: Results from psoriasis symptoms diary at week 12

	Secukinumab 300 mg (n = 117)	Secukinumab 150 mg (n = 117)	Etanercept (n = 116)	Placebo (n = 109)
Itching Pain Scaling	−4.93 (0.25) ϯ§ -4.48 (0.28) ϯ§ -4.93 (0.26) ϯ§	−4.92 (0.25) ϯ§ -4.10 (0.28) ϯ¶ -4.89 (0.24) ϯ§	−3.80 (0.26) -3.48 (0.25) -3.74 (0.26)	−0.54 (0.20) -0.33 (0.22) -0.42 (0.22)

Ϯ P < 0.001 versus Placebo

§ P < 0.001 versus Etanercept

¶ P < 0.05 versus Etanercept

Figure 3. QoL improvement at 1-year follow-up with EQ-5D-3 L in CLEAR. Data assessed with non-responder imputation. Ustekinumab dose: 45 mg for patients weighing ≤100 kg at baseline or 90 mg for patient weighing >100 kg. QoL, quality of life; SEC, secukinumab; UST, ustekinumab

Figure 4. Changes in DLQI (A) and Family DLQI (B) after treatment with secukinumab in patients with psoriasis stratified by prior treatment history. Adapted from [52] with permission

Table 3. CORRONA Psoriasis Registry: changes in patient-reported outcomes at 6 months

	Baseline	6 months
Itching	51.9	21.1*
Pain	37.1	13.9*
Fatigue	34.6	26.1*
EQ-VAS	70.2	77.2*
DLQI score 0/1	12.8%	55.1%*

*P < 0.01 vs. baseline.

Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;30:95–103.

 PubMed Web of Science ®Google Scholar

Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2020. https://doi.org/https://doi.org/10.1111/jdv.16632.

 Google Scholar